Xspray Pharma Dirección

Dirección controles de criterios 2/4

El CEO de Xspray Pharma es Per Andersson , nombrado en Jan 2006, tiene una permanencia de 18.75 años. compensación anual total es SEK3.74M, compuesta por 70.5% salario y 29.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.57% de las acciones de la empresa, por valor de SEK9.38M. La antigüedad media del equipo directivo y de la junta directiva es de 0.9 años y 5.4 años, respectivamente.

Información clave

Per Andersson

Chief Executive Officer (CEO)

SEK 3.7m

Compensación total

Porcentaje del salario del CEO	70.5%
Permanencia del CEO	18.8yrs
Participación del CEO	0.6%
Permanencia media de la dirección	less than a year
Promedio de permanencia en la Junta Directiva	5.4yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Per Andersson en comparación con los beneficios de Xspray Pharma?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	-SEK 215m
Mar 31 2024	n/a	n/a	-SEK 213m
Dec 31 2023	SEK 4m	SEK 3m	-SEK 180m
Sep 30 2023	n/a	n/a	-SEK 180m
Jun 30 2023	n/a	n/a	-SEK 170m
Mar 31 2023	n/a	n/a	-SEK 148m
Dec 31 2022	SEK 4m	SEK 2m	-SEK 132m
Sep 30 2022	n/a	n/a	-SEK 128m
Jun 30 2022	n/a	n/a	-SEK 114m
Mar 31 2022	n/a	n/a	-SEK 102m
Dec 31 2021	SEK 3m	SEK 2m	-SEK 97m
Sep 30 2021	n/a	n/a	-SEK 60m
Jun 30 2021	n/a	n/a	-SEK 57m
Mar 31 2021	n/a	n/a	-SEK 56m
Dec 31 2020	SEK 3m	SEK 2m	-SEK 52m
Sep 30 2020	n/a	n/a	-SEK 56m
Jun 30 2020	n/a	n/a	-SEK 55m
Mar 31 2020	n/a	n/a	-SEK 49m
Dec 31 2019	SEK 3m	SEK 2m	-SEK 46m
Sep 30 2019	n/a	n/a	-SEK 41m
Jun 30 2019	n/a	n/a	-SEK 34m
Mar 31 2019	n/a	n/a	-SEK 30m
Dec 31 2018	SEK 2m	SEK 2m	-SEK 23m
Sep 30 2018	n/a	n/a	-SEK 17m
Jun 30 2018	n/a	n/a	-SEK 16m
Mar 31 2018	n/a	n/a	-SEK 8m
Dec 31 2017	SEK 2m	SEK 1m	-SEK 14m

Compensación vs. Mercado: La compensación total de Per($USD360.81K) está por debajo de la media de empresas de tamaño similar en el mercado UK ($USD743.85K).

Compensación vs. Ingresos: La compensación de Per ha aumentado mientras la empresa no es rentable.

CEO

Per Andersson (57 yo)

18.8yrs

Permanencia

SEK 3,743,000

Compensación

Dr. Per Andersson Ph.D. has been the Chief Executive Officer of Xspray Pharma AB (publ) since 2006. Dr. Andersson serves as the Chief Executive Officer of Xspray Microparticles AB. Dr. Andersson joined XSp...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Per Andersson	Chief Executive Officer	18.8yrs	SEK 3.74m	0.57% SEK 9.4m
Mustafa Demirbüker	Co-Founder and Science Director	no data	sin datos	sin datos
Niklas Adenborg	Chief Financial Officer	less than a year	sin datos	sin datos
Linda Glimberg	Chief Operating Officer	less than a year	sin datos	0.0053% SEK 87.0k
Kerstin Hasselgren	Senior Advisor & Head of IR	less than a year	sin datos	0.024% SEK 398.8k
Charlotta Liljebris	Senior Vice President of Research & Development	6.8yrs	sin datos	0.0089% SEK 145.1k
Edward Jordan	Chief Commercial Officer	1.1yrs	sin datos	sin datos
Anette Abrahamsson	Senior Vice President of Regulatory Affairs	less than a year	sin datos	0.0044% SEK 72.5k
Christer Hallgren	Senior Vice President of Intellectual Property	6.8yrs	sin datos	0.089% SEK 1.5m

0.9yrs

Permanencia media

56.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 0GHZ no se considera experimentado ( 0.9 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Maris Hartmanis	Independent Director	9.8yrs	SEK 323.00k	0.092% SEK 1.5m
Carl-Johan Spak	Independent Director	9.8yrs	SEK 270.00k	sin datos
Anders Ekblom	Chairman	3.4yrs	SEK 510.00k	1.71% SEK 27.9m
Torbjörn Koivisto	Independent Director	7.8yrs	SEK 253.00k	sin datos
Christine Lind	Independent Director	5.4yrs	SEK 270.00k	sin datos
Anders Bladh	Director	3.4yrs	SEK 253.00k	2.49% SEK 40.7m
Robert Molander	Independent Director	2.4yrs	SEK 218.00k	0.030% SEK 483.5k

5.4yrs

Permanencia media

66yo

Promedio de edad

Junta con experiencia: La junta directiva de 0GHZ se considera experimentada (5.4 años de antigüedad promedio).

Xspray Pharma Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Xspray Pharma AB (publ), Annual General Meeting, May 13, 2025

Xspray Pharma AB's Nomination Committee for the Annual General Meeting 2025

Director recently bought kr4.8m worth of stock

Director recently bought kr143k worth of stock

Insufficient new directors

Insufficient new directors

Recent updates

Xspray Pharma AB (publ) to Report Fiscal Year 2024 Final Results on Mar 27, 2025

Xspray Pharma AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 135.04904 million.

Xspray Pharma AB (publ), Annual General Meeting, May 13, 2025

Xspray Pharma AB's Nomination Committee for the Annual General Meeting 2025

Xspray Pharma Announces Positive FDA Meeting and Plans for Dasynoc NDA Resubmission

Director recently bought kr4.8m worth of stock

Director recently bought kr143k worth of stock

Insufficient new directors

Xspray Pharma Ab's Xs003 Study Shows Matching Bioavailability to Tasigna At More Than A 50% Lower Dose

Insufficient new directors

Xspray Pharma AB (publ) Announces to Present Data At ASCO Highlighting Frequent Decideication of PPIs with TKIs in CML-Patients and Greater Than Expected Positive Effects on the Bioavailability of Crystalline Dasatinib

Xspray Pharma AB (publ) to Report Fiscal Year 2024 Results on Feb 12, 2025

Xspray Pharma AB (publ) to Report Q2, 2024 Results on Aug 07, 2024

FDA Accepts Xpray Pharma's NDA-Resubmission for Dasynoc® - PDUFA

Xspray Pharma AB (Publ) Announces CFO Changes

Director recently bought kr2.1m worth of stock

Director recently bought kr395k worth of stock

Xspray Pharma Ab's Xs003 Achieves Superior Bioavailability Milestone, Matching TASIGNA At Reduced Dosage

Director recently bought kr5.0m worth of stock

New minor risk - Shareholder dilution

Xspray Pharma AB Through HyNap™ technology Announces Results from Drug Interaction Studies

Forecast to breakeven in 2024

Xspray Pharma AB (publ), Annual General Meeting, May 21, 2024

New major risk - Financial position

Xspray Pharma Appoints Edward P. Jordan as Chief Commercial Officer

Xspray Pharma and Bristol Myers Squibb Reach Settlement on Dasynoc Patent Litigation, Paving Way for Early Market Launch

Forecast to breakeven in 2024

Xspray Pharma AB (publ) to Report Q4, 2023 Results on Feb 14, 2024

Xspray Pharma AB (publ) Receives Request for Additional Information Concerning Dasynoc from FDA

Forecast to breakeven in 2024

Xspray Pharma AB (publ) to Report Q3, 2023 Results on Nov 08, 2023

Forecast to breakeven in 2024

Director recently bought kr2.6m worth of stock

Xspray Pharma AB (publ)'s Drug Candidate Xs004 Granted Orphan Drug Designation in the US for the Treatment of Acute Lymphoblastic Leukemia

Forecast to breakeven in 2024

Xspray Pharma AB (publ), Annual General Meeting, May 16, 2023

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Xspray Pharma AB Appoints Thomas Walz to the Newly Established Position Chief Medical Officer

Xspray Pharma AB (publ) Approves Election of Robert Molander as Member of its Board of Directors

Forecast to breakeven in 2024

Xspray Pharma AB (publ) to Report Fiscal Year 2022 Results on Feb 17, 2023

Xspray Pharma AB (publ), Annual General Meeting, May 19, 2022

Xspray Pharma AB (Publ) Appoints Anna-Karin as Global Head of Marketing and Sales, Effective March 15, 2022

Xspray Pharma AB (Publ) Announces Fda Allows Review of Application for Market Approval for Dasynoc™

Forecast breakeven date pushed back to 2024

No longer forecast to breakeven

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad